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Human pharmacology of 5-epi-sisomicin (Sch 22591)
following intramuscular administration
J. Blaser, R. Munch and R. Lutfay
Department of Medicine, University Hospital, Zurich, Switzerland
5-epi-sisomicin was given as a single intramuscular injection of 1 mg/kg to six
healthy male adults. Serum peak concentrations averaged 3-07 mg/1, the mean
elimination half life was 179 min and the mean 24 h urinary recovery was 85-3%.
Local and systemic tolerance was good.
Introduction
5-epi-sisomicin (Sch 22591) is a semisynthetic aminoglycoside which is derived from
sisomicin (Testa et al., 1974). Introduction of a hydroxy group in position 5 of the
deoxystreptamine ring results in an enhanced antibacterial activity against a great
variety of Gram-positive and Gram-negative bacteria (Fu & Neu, 1978; Kabins &
Nathan, 1978; Sanders, Sanders & Goering, 1978; Watanakunakorn, 1978).
5-epi-sisomicin is either not, or less effectively, modified by most aminoglycoside
modifying enzymes (Waitz et al., 1978; Vastola, Altschaefl & Harford, 1980). In
addition, 5-epi-sisomicin appears to be superior to other aminoglycosides in protecting
mice infected with Pseudomonas aeruginosa (Goering, Sanders & Sanders, 1978; Waitz
et al., 1978). The purpose of this study was to investigate the pharmacokinetics of
5-epi-sisomicin in humans after intramuscular injection of 1 mg/kg body weight and to
evaluate local and systemic tolerance.
The results of this study have been presented previously as an extended abstract
(Liithy, Munch & Blaser, 1980). Recently data from a similar study have been reported
in this Journal (Amirak et al., 1985). However, some results presented in the paper by
Amirak et al. (1985) differ substantially from the pharmacokinetic data obtained in
our study. Hence, these data are presented here in detail and methodological
differences between the two studies are addressed in the discussion.
Methods
Six healthy male volunteers, 21-28 years old, with a mean body weight of 69 kg
( + 11-5 kg, S.D.) were enrolled in this study. The study was performed according to
institutional policies, with written informed consent obtained from each participant. A
dose of 1 mg/kg of 5-epi-sisomicin was injected into the upper outer quadrant of the
gluteal area. Thirteen venous samples were withdrawn from an arm vein, before the
administration and 15, 30, 45, 60 and 90 min and 2, 3, 4, 6, 8, 12 and 24 h following
the im dose. After clotting at room temperature blood samples were centrifuged at
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4°C. Urine was sampled quantitatively during a 24 h period before administration of
the drug and in seven fractions over a 72 h period following the injection. Serum and
urine standards in the range of the expected concentrations were prepared on the study
day with pooled antibiotic free human serum and 0-05 M phosphate buffer, pH 7,
respectively. All standards and samples were frozen in liquid nitrogen and assayed
within one week with a large plate agar diffusion method (Bennet et al., 1966).
Concentrations of 5-epi-sisomicin in the range of 0-5-8 mg/1 were assayed in
quintuplicate with Bacillus subtilis (spore suspension, Difco Laboratories, Detroit
Michigan, U.S.A.) as the assay organism. Concentrations in the range of
0-016-0-5 mg/1 were determined in quintuplicate with Staphylococcus epidermidis
(ATCC 27626) as the assay organism. The precision of the assay was determined with
ten spiked serum specimens in the range of 0-016-8 mg/1. Each of these specimens was
measured five times, revealing a coefficient of variation of 5-8%.
Before and after study the following laboratory examinations were performed:
haematocrit, haemoglobin, a complete blood count, erythrocyte sedimentation rate,
fasting blood sugar, blood urea, nitrogen, serum creatinine, bilirubin, alkaline
phosphate, transaminases, and total protein with albumin/globulin ratio. Complete
urine analyses including microscopic examination were conducted. A 24 h creatinine
clearance was determined before, during and after the study day.
Serum kinetics during the first 12 h after administration of the drug were analysed
by an open two compartment model (Gibaldi & Perrier, 1975). The pharmacokinetic
parameters of the model (volume of distribution of the central compartment V1, rate
constants for transfer between the two compartments kl2 and k21 and rate constants
o-oi
Time ( h )
Figure 1. Mean and range of serum concentrations of 5-epi-sisomicin in six human subjects, following im
administration of 1 mg/kg.
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of absorption ka and elimination ke) were determined with a nonlinear fitting
programme (Metzler, Elfring & McEwen, 1974). The total volume of distribution
, body clearance (CIb) and elimination half life (Tl/2) were defined as follows:
V^= V, * (1 +kl2/k21); Clb = ke • V,; Tm = In 2jke.
Results
Serum kinetics of 5-epi-sisomicin are shown in Figure 1. Peak serum levels (±S.D.)
averaged 307 + 0-44 mg/1. The maximal concentrations were measured between 45 and
90 min after administration. The individual serum concentrations are given in Table 1.
In five out of the six subjects 24 h serum concentrations were still above the sensitivity
limit of the assay (0016 mg/1), with an average concentration of 002 mg/1. Analysis of
the serum data from the first 12 h revealed a mean serum half life of 179 + 20 min, a
total volume of distribution of 15-9+1-91 (0-23 + 003 I/kg) and a body clearance of
78-4ml/min per 1-73 m2 body surface area (84-3 + 16ml/min), respectively. The half
life of absorption from the muscular depot was determined as 46+ 13 min.
Urinary recovery averaged 83-1% (range 79-6-89-3%) for the first 12 h and 92-2%
(88-7-99-5%) for the first 72 h (Figure 2). The urinary excretion rate decreased
exponentially from 15-5% of the dose per hour in the first 4h interval to less than
0-2%/h after 12 h. From 36 to 72 h the hourly excretion rate remained constant at a
level of 0 1 % of the administered dose. These data suggest a continuing excretion
beyond the last collection period.
One patient had diarrhoea one day after drug administration, two reported dull
pressure in the head for less than 12 h and one subject reported a faint pressure in both
ears lasting 15 min. No significant changes in the haematology, serum chemistry or
urine analysis were recorded. No local side effects attributable to 5-epi-sisomicin were
recorded.
Discussion
The serum kinetics of 5-epi-sisomicin were studied in six healthy volunteers. Compared
to other aminoglycoside antibiotics the peak concentrations of 3 07 mg/1 following im
doses of 1 mg/kg were rather low (Gruenwaldt et al., 1976; Riff & Moreschi, 1977).
However, Meyers et al. (1976) also observed peak levels of 308 mg/1 for sisomicin.
Amirak et al. (1985) reported for 5-epi-sisomicin a mean peak concentration of
4-82 mg/1 which is 57% higher than that found in the present study. This discrepancy
might be explained in part by the fact that in the study of Amirak et al. (1985) the
standards were prepared in horse serum as opposed to pooled human serum in the
present study. The mean volume of distribution of 5-epi-sisomicin (0-23 I/kg) is
comparable to data reported for other aminoglycosides (Schentag et al., 1977; Blaser
et al., 1983a, b).
The serum concentrations declined within the first 12 h after the dose according to a
mean serum half life of almost 3 h. This is longer than half lives reported for other
aminoglycosides in healthy young subjects (Gruenwaldt et al., 1976; Blaser et al.,
1983a). The glomerular filtration rate of the six subjects was normal, with a mean
creatinine clearance of 137ml/min and serum creatinine values between 0-7 and
11 mg/100 ml. Amirak et al. (1985) reported a mean serum half life for 5-epi-sisomicin
of 2-3 h. However, these data were derived only from serum concentrations measured
Table I. Serum concentrations of 5-epi-sisomicin (mg/1) in six human volunteers following im administration of 1 -0 mg/kg
Subject 0-25 0-5 0-75
Time after drug administration (h)
1-5 2 3 4 12 24 W
1
2
3
4
5
6
2-58
1-68
2-85
200
1-70
104
302
2-38
3-46
2-90
2-50
205
3-33
2-70
3-81
2-80
2-67
2-48
2-91
2-73
3-45
315
2-74
2-63
2-59
2-51
2-84
2-70
2-10
2-68
2-30
2-56
2-33
2-26
1 88
2-64
173
2-04
1-77
1-58
1-40
204
1-22
•29
•53
•27
•00
•44
0-86
0-70
0-78
0-88
0-59
0-79
0-57
0-45
0-47
0-54
0-33
0-48
0-25
0-20
019
018
016
018
0025
0016
0023
0020
<0016
0017
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Figure 2. Mean and range of urinary elimination rate (full line, left hand scale) and cumulative urinary
recovery rate (broken line, right hand scale) in six human subjects, following im administration of
1 mg/kg.
within the first 4 h after dosing. After this time the serum levels fell below the detection
limits (> 1 mg/1) of the assay used in their study. The low sensitivity limit of the assay
used in the present study (0016 mg/1) allowed us to determine serum levels for up to
24 h after the administration of the dose.
However, the analysis of the serum data by means of a two compartment open
model was limited to the 12 h period after drug administration. The 24 h serum
concentrations had to be excluded because they were consistently higher than expected
according to the half-life of elimination found during the first 12 h (Figure 1). For
simulations over a longer time period a three compartment model would be needed.
This finding is consistent with the concept of the presence of a deep compartment in
which aminoglycoside antibiotics accumulate in the course of therapy (Schentag et al.,
1977; Blaser et al., 1983a, b). The urinary excretion data strongly support this concept.
After a distinct exponential decline of the urinary excretion rate during the initial 12 h
period, the renal elimination remains fairly constant during the following 60 h. These
data suggest the existence of a deep compartment which releases the accumulated drug
at the rate of approximately 0-1 % of the administered dose per hour. The urinary
recovery rate of 92-2 + 4-8% (mean + s.D.) after 72 h together with the finding of the
prolonged elimination which appears to continue beyond 72 h suggest that no
significant non-renal elimination occurs.
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